Advanced Search


Study ID Status Title Patient Level Data
CNAF3016 Completed A Pilot Study to assess the Efficacy and Safety of a quadritherapy with Combivir, Abacavir, Nelfinavir switching from week 16 to (TZV), Nelfinavir for Antiretroviral Therapy in HIV-infected Naive Subjects with a viral load > 50 000 copies/mL
CNAF3021 Completed Long term follow-up of 2 triple combinations CombivirTM + Ziagen™ and Combivir™ + Viracept™ started in HIV-1 infected antiretroviral therapy naïve subjects within 2 years in study CNAF3007-Ecureuil.
COD10001 Completed A pilot open-labeled, randomized, parallel cohort, pharmacokinetic and pharmacodynamic, multicenter trial of zidovudine (RETROVIR) 600 mg once daily compared to zidovudine 300 mg BID monotherapy for 14 days in HIV infected, therapy naïve patients.
COD20002 Completed A Phase II, Open-Label, Multicenter, Randomized, Parallel Group, 14 Day Pilot Study of Monotherapy with Zidovudine 600mg Once Daily Compared to Zidovudine 300mg Twice Daily in HIV-Infected, Antiretroviral-Naïve Subjects.
COL30267 Completed Initial title: Evaluation of efficacy and safety of combination of Combivir TM(AZT/3TC) and abacavir, in HIV-infected patients with an abacavir-susceptible phenotype and who had received Zerit ® (d4T) and Videx ® (ddl) as first-line treatment with or without non nucleosidic…
COL30281 Completed An open label, randomised study, to evaluate the safety and efficacy of Combivir plus abacavir (Ziagen) versus Combivir plus Viracept, in HIV-1 infected antiretroviral therapy naive adults with a plasma HIV-1 RNA between 1000 and 500,000 copies /mL.
COL30305 Completed A Phase IV, Randomized, Open-Label, Multi-center, Twenty-Four-Week Pilot Study to Evaluate the Efficacy and Safety of Continued Therapy with Two Nucleoside Reverse Transcriptase Inhibitors…
COL30330 Completed A Phase I, 13-Day, Controlled, Open-Label Pharmacokinetic Evaluation of Methadone Following Co-Administration with Amprenavir in Opiate-Dependent Subjects
COL30336 Completed A Phase IV, Open-Label, Multicenter Study of the Efficacy and Safety of Quadruple Combination Antiretroviral Therapy with COMBIVIR (Lamivudine 150mg/Zidovudine 300mg) BID, ZIAGEN (Abacavir) 300mg BID, and SUSTIVA (Efavirenz) 600mg QD for 24 Weeks, Followed by Therapy with the Triple Nucleoside C ...
COL30352 Completed A pilot study to evaluate the efficacy and safety of a combination of antiretroviral drugs including amprenavir with or without ritonavir, two or three nucleoside analogs in HIV-1 infected patients who are in virological escape after a first, second or third line therapy including at least one p ...
COL30406 Completed A Study to Investigate the Pharmacokinetic Interaction Between Amprenavir and Ritonavir Following Their Co-Administration in Subjects with HIV-1 infection (PROF1003).
COL30436 Completed A compassionate use study to evaluate the safety and efficacy of COMBIVIR™ (lamivudine [LAM]150mg/zidovudine [ZDV] 300mg) tablets and AGENERASE™ (Amprenavir) (APV 150mg) capsules in human immunodeficiency (HIV) virus positive patients with CD4 cell count of 100 - 500/mm3 seen at Jos University T ...
COL30441 Completed A Pilot, Multicentre Study to Evaluate the Efficacy and Safety of an Antiretroviral Therapy with Trizivir [abacavir, lamivudine, zidovudine] and Efavirenz after a 14-week Structured Antiretroviral Treatment Interruption, in HIV-1 Infected Subjects with a Viral Load > 5000 copies/mL…
COL30470 Completed A Pilot, Randomised, Open-Label, Monocenter Study to Evaluate the Safety and Efficacy of a Quadruple Combination Therapy of Triple Combination Tablet (Trizivir) [abacavir, lamivudine, zidovudine] Plus Saquinavir-SGC/Ritonavir Versus Triple Combination Therapy of Combivir Plus Saquinavir-SGC/Rito ...
COL30494 Completed An Open-Label Multicentre Study to Evaluate the Adherence to, General Satisfaction and Quality of Life After 24 Weeks Therapy With a Triple Combination tablet (TRIZIVIR™) [Abacavir, Lamivudine, and Zidovudine] in HIV-1 Infected Subjects With Undetectable Plasma HIV-1 RNA Levels
COL30500 Completed An Open-Label, Single-Arm Study to Assess the Effect of Efavirenz (600mg QD) on Steady-State Plasma Amprenavir Pharmacokinetics Following Co-Administration with AGENERASE (1200mg QD), Ritonavir (300mg QD), Abacavir (300mg BID), and Lamivudine (150mg BID) in Adult HIV-Infected Subjects.
COL30527 Completed The pharmacokinetics and bioequivalence of lamotrigine capsules and tablets, and effect of food on lamotrigine tablets.
COL30528 Completed An open label study to evaluate long term (96 weeks) safety and efficacy of switch to TRIZIVIR after first line quadruple induction therapy: AZLF 3006 – Suburbs 2
COL30573 Completed Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients with Human Immunodeficiency Virus Infection
COL30574 Completed A phase IIIB, non-comparative, single arm, open-label, multicenter study on antiviral efficacy and safety of the approach “Induction- Maintenance” in patients with HIV-1 infection naïve to antiretroviral therapy. A 72-week study on the scheme: induction with TRIZIVIR® + SUSTIVA® or COMBIVIR® + SUSTI
COL40263 Completed A Pilot, Open-Label, Multi-Center Study to Evaluate the Efficacy and Safety of a Once-Daily Regimen of Trizivir in Combination with Tenofovir Disoproxil Fumarate in Antiretroviral Therapy-Naïve Subjects with Viral Loads ?30,000 copies/mL
COL40287 Completed The Pharmacokinetic Interaction of a Triple Protease Inhibitor Regimen Containing Fosamprenavir, Lopinavir, and Ritonavir in Healthy Volunteers
COLA2012 Completed A Phase II, 192-Week, Uncontrolled, Open-Label Study Designed to Evaluate the Safety and Efficacy of Novel and Highly Potent Antiretroviral Therapy (Protease Inhibitor and Nucleoside Reverse Transcriptase Inhibitor Based) in Subjects Acutely Infected with HIV-1. (GW QUAD 3)
COLA3003 Completed A Phase II, 48-Week, Uncontrolled, Open-Label Study Designed to Evaluate Cellular Dynamics and Immune Restoration In Peripheral Blood and Lymphoid Tissue in Antiretroviral-Naïve, HIV-Infected Subjects Receiving a Triple-Drug Regimen Comprised of Amprenavir (600mg BID), Ritonavir (100mg BID), Aba ...
COLA4005 Completed A Phase II, Open-Label, Randomized Study of the Efficacy and Safety of EPIVIR 150mg Twice-Daily Versus EPIVIR 300mg Once-Daily When Administered for 24 Weeks in Combination with FDA-Approved Dosage Regimens of ZERIT and Either CRIXIVAN or VIRACEPT in Subjects with HIV-1 Infection



For more information on this register please email

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party. is a database that provides summary protocol information for ongoing clinical trials. is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.